Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 188 Show results per page	View Search Criteria \| Help With Results


1.		A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Natural history/Epidemiology, Treatment				Closed				Age not specified				Pharmaceutical / Industry				AVF2941n NCT00097578


2.		A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				ML18491 NCT00118755


3.		A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				ML18527 NCT00121836


4.		A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				MO19390 NCT00451906

Last Modified: 6/3/2008 First Published: 7/1/2001


5.		Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Advanced, Metastatic, or Recurrent Non-Squamous Cell Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI				ECOG-4599 CALGB-E4599, E4599, NCT00021060


6.		The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Other				AG0501CR NCT00294359

Last Modified: 1/16/2008 First Published: 3/1/2001


7.		Phase III Randomized Study of Bevacizumab (rhuMAb VEGF) With Fluorouracil and Leucovorin Calcium With or Without Irinotecan in Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GENENTECH-AVF2107g UCLA-0008022, NCT00012233

Last Modified: 9/6/2005 First Published: 3/1/2001


8.		Phase III Randomized Study of Bevacizumab With Capecitabine Versus Capecitabine Alone in Women With Previously Treated Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				GENENTECH-AVF2119g GUMC-00299, MSKCC-01008, UAB-0028, UAB-F001009003, NCT00012285

Last Modified: 6/15/2007 First Published: 10/1/2001


9.		Phase III Randomized Study of Oxaliplatin, Fluorouracil, and Leucovorin Calcium With or Without Bevacizumab Versus Bevacizumab Only in Patients With Previously Treated Advanced or Metastatic Colorectal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				E-3200 NCT00025337, E3200

Last Modified: 1/8/2008 First Published: 1/1/2002


10.		Phase III Randomized Study of Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				ECOG-2100 NCCTG-E2100, CAN-NCIC-MAC3, NSABP-E2100, E2100, NCT00028990, MAC3

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute